Canadian premiers go to Washington in bid to convince Trump to drop tariffs
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
FTSE 100 LIVE: Markets calm as EU readies plan for no-deal trade scenario with US
The FTSE 100 (^FTSE) and European stocks were tepid on Monday morning, making small moves as the EU prepares a plan for a potential no-deal scenario in trade negotiations with the US. Leaders are set to meet early this week, according to a Bloomberg report, in order to formulate a plan ahead of the 1 August deadline set by president Donald Trump. As it stands, the US plans to implement tariffs on EU imports at 10% or higher, with fewer exemptions than once offered on the table, according to Bloomberg. Medical supplies, aviation and manufacturing equipment are among the items being haggled over. Negotiations are set to continue over the next fortnight. In previous weeks, the EU prepared a list of items imported from the US that it was prepared to slap higher levies on in order to strengthen its stance, while the US sent a letter saying the bloc would face a 30% tariff after the 1 August deadline, among other stipulations. London's premier index rose around 0.1% in early such as Antofagasta (ANTO.L), Anglo American (AAL.L) and Glencore (GLEN.L) led the index higher. Over in Germany, the DAX (^GDAXI) was flat. The CAC 40 (^FCHI) in Paris fell below the flatline. The pan-European STOXX 600 (^STOXX) also lacked direction, hovering slightly higher. Here's the US stock futures chart US stock futures higher as earnings season continues Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Average UK house price down £5,000 The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK Good morning! Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Here's the US stock futures chart US stock futures higher as earnings season continues Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Our US team writes: US stock futures rose early Monday morning, as markets entered a critical week defined by megacap earnings and continued risk around President Trump's looming tariffs. S&P 500 (ES=F) futures climbed 0.2%, contracts on the Nasdaq 100 (NQ=F) gained 0.3%, while Dow Jones Industrial Average futures (YM=F) inched up 0.1%, reflecting a cautious tone after last week's record-setting rally in growth names. The Nasdaq advanced 1.5% last week, while the S&P 500 added 0.6%. The Dow lagged, finishing slightly negative. Investor focus is dominated by two topics for the upcoming week: policy clarity on trade and earnings from tech heavyweights. On Sunday, Commerce Secretary Howard Lutnick reaffirmed the White House's August 1 deadline for new tariffs, calling it a "hard stop" for compliance — before saying that he's looking at continued conversation beyond that date. Read more on Yahoo Finance Average UK house price down £5,000 The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK The average price of a UK property coming to the market in July dropped by 1.2% to £373,709 in the largest monthly price drop at this time of year recorded in over 20 years of data, as new sellers lower their price expectations, according to Rightmove (RMV.L). According to the property site, this month's price drop of £4,531 comes as sellers lower expectations to catch buyers' attention amid a high supply of homes for sale. London, the country's largest regional market, leads the charge in price reductions with an overall drop of 1.5%, driven largely by Inner London, where prices fell by 2.1%. This market shift comes as sellers in the capital react to external factors, including changes to stamp duty and tax rules, while also trying to compete for the growing pool of potential buyers. Despite the price reductions, buyers are still active, with the number of sales agreed up 5% compared to this time last year. Furthermore, inquiries from potential buyers are 6% higher than in 2023, indicating continued demand. At the same time, affordability is improving for many buyers, helped by lower mortgage rates and rising wages. Read more on Yahoo Finance UK Good morning! Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Hello from London. Lucy Harley-McKeown here, gearing up to bring you the latest markets and economics headlines. This morning we have an update on UK house prices and also a trading statement from budget carrier Ryanair ( Trade tensions between the EU and US are also hotting up, so we'll be watching that, too. Let's get to it. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
SS&C Technologies to Acquire Calastone
WINDSOR, Conn., July 21, 2025--(BUSINESS WIRE)--SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced a definitive agreement to acquire Calastone, the largest global funds network and leading provider of technology solutions to the wealth and asset management industries, from global investment firm Carlyle. The purchase price is approximately £766 million (approximately US $1.03 billion), subject to certain adjustments. Headquartered in London, Calastone operates the largest global funds network, connecting more than 4,500 of the world's leading financial organizations across 57 markets. The acquisition is expected to close in Q4 2025, subject to regulatory approvals. SS&C expects the acquisition to be accretive within 12 months and plans to fund the purchase with a combination of debt and cash on hand. Calastone's more than 250 staffers in London, Luxembourg, Hong Kong, Taipei, Singapore, New York and Sydney are expected to join SS&C Global Investor & Distribution Solutions, reporting to General Manager Nick Wright. "We're excited to welcome Julien, the Calastone team and their valued clients to SS&C," said Bill Stone, Chairman and CEO of SS&C Technologies. "Together, we will create a more connected, automated, and intelligent global fund ecosystem — reducing complexity, enhancing client experience, and shaping the future of distribution and investment operations." The acquisition of Calastone reinforces SS&C's commitment to transforming investment operations and bolsters SS&C's ongoing geographic expansion. Calastone's global network and technology solutions complement SS&C's leadership in fund administration, transfer agency services, AI and intelligent automation. By combining capabilities, the two companies will deliver a unified, real-time operating platform to reduce cost, complexity, and operational risk across the global fund ecosystem as well as shaping distribution. This strategic alignment enables enhanced distribution, investor servicing, and operational scalability — empowering asset and wealth managers to innovate, diversify products, and deliver better outcomes for investors worldwide. "We are pleased to be combining forces with SS&C in our joint mission to build the most comprehensive, intelligent and connected wealth and asset management ecosystem," said Julien Hammerson, CEO of Calastone. "SS&C's global scale and deep expertise across fund services and technology will enable us to accelerate innovation and deliver new digital capabilities to the market. We look forward to working together to deliver transformational services to asset and wealth managers and drive growth." Fernando Chueca, Managing Director on the Carlyle Europe Technology Partners investment advisory team, said: "We are pleased to have supported Calastone through such a transformational period of growth for the business. Its well-established technology network represents a differentiated, automated offering and we believe the business is well-positioned to build upon its market position and business momentum. We are confident that SS&C is the right partner to continue Calastone's success, and we look forward to watching the company thrive in its next phase." SS&C was advised by Davis Polk & Wardwell LLP. Barclays served as exclusive financial advisor to Calastone and Linklaters and Mishcon De Reya served as legal advisors to Calastone in connection with the transaction. About Calastone Calastone is the largest global funds network, connecting the world's leading financial organisations. Calastone's mission is to reduce complexity, risk and costs, enabling the industry to deliver greater value to investors. 4,500 clients in 57 countries and territories benefit from Calastone's services, processing over £250 billion of investment value each month. Calastone is headquartered in London and has offices in Luxembourg, Hong Kong, Taipei, Singapore, New York and Sydney. About SS&C Technologies SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale, and technology. About Carlyle Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group. Additional information about SS&C (Nasdaq:SSNC) is available at SS&C on X, LinkedIn and Facebook. View source version on Contacts Brian SchellChief Financial OfficerSS&C TechnologiesTel: +1-816-642-0915E-mail: InvestorRelations@ Justine StoneInvestor RelationsSS&C TechnologiesTel: +1- 212-367-4705E-mail: InvestorRelations@ Media Contacts Sam GentileTel : +1-646-818-9195Email : pro-SSC@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Cell‑Based Assays Report 2025: Key Market Drivers, Tech Trends & Competitive Landscape to 2030
The global cell-based assays market is set to grow from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, marking a CAGR of 9.1%. This surge is fueled by the rising demand in drug discovery and increased R&D investments by the pharmaceutical and biotech industries. The prevalence of cancer is boosting the need for advanced therapies, while the growth of cell-based assays applications in chronic diseases and personalized medicine further propels market expansion. In 2024, the drug discovery and flow cytometry segments dominated the market. The US, with its strong healthcare infrastructure and biopharmaceutical industry, led the global market. Key companies in this sector include BD, Thermo Fisher Scientific, and Merck KGaA. Cell Based Assays Market Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "Cell Based Assays Market by Offering (Consumables (Reagents, Assay Kits, Cell Lines, Microplates, Probes, Labels), Instruments & Software), Technology (Flow Cytometry, HTS), Application (Drug Discovery (Toxicity, PK/PD Studies)) - Global Forecast to 2030" has been added to global cell-based assays market is anticipated to expand from USD 17.84 billion in 2025 to USD 27.55 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. This growth is fueled by escalating demand in drug discovery and the increasing need for sophisticated therapies, particularly in oncology. An uptick in research and development investments from pharmaceutical and biotechnology firms is another catalyst propelling market expansion. Drug Discovery's Dominance in Applications Within the applications segment, drug discovery is poised to retain its prominence through 2024. It encompasses subcategories such as toxicity, pharmacokinetics, and pharmacodynamics studies. The segment's ascendancy is largely attributed to the burgeoning incidence of cancer, which heightens demand for novel therapies. Additionally, robust investments and the emergence of contract research organizations are significantly advancing drug discovery efforts. Flow Cytometry Leads Technological Innovations In 2024, the flow cytometry segment emerged as a leader within the technology category, driven by its pivotal role in providing comprehensive cell-based assay measurements. Enhanced adoption of cutting-edge technologies for cell analysis continues to bolster this sector, ensuring its sustained growth trajectory. Regional Insights and U.S. Market Leadership The U.S. held a commanding position in the North American market in 2024, attributed to its stature as the largest biopharmaceutical hub globally. This leadership is strengthened by significant research investments and a robust healthcare framework. The emphasis on developing advanced cell-based therapies is a key driver in response to rising cancer cases. Notable Market Players: BD (US) Thermo Fisher Scientific Inc. (US) Danaher Corporation (US) Merck KGaA (Germany) Agilent Technologies, Inc. (US) Lonza (Switzerland) Charles River Laboratories (US) Bio-Rad Laboratories, Inc. (US) REVVITY (US) Sartorius AG (Germany) And others Research Coverage and Market Insights: The report categorizes the cell-based assays market based on offerings, technology, applications, end users, and regions. It elucidates major drivers, restraints, opportunities, and challenges influencing market dynamics. Additionally, a comprehensive analysis of key industry players, including product launches, collaborations, and acquisitions, sheds light on the competitive landscape. Key Insights for Stakeholders: Drivers such as increasing demand for drug discovery, rising prevalence of cancer, and heightened R&D investments. Constraints involving high costs and licensing restrictions. Opportunities in chronic diseases and personalized medicine sectors. Competitive assessment of major players highlighting their strategies and market positioning. Key Attributes: Report Attribute Details No. of Pages 449 Forecast Period 2025 - 2030 Estimated Market Value (USD) in 2025 $17.84 Billion Forecasted Market Value (USD) by 2030 $27.55 Billion Compound Annual Growth Rate 9.1% Regions Covered Global Key Topics Covered: Market Dynamics Drivers Growing Demand For Drug Discovery & Development and Increasing Preference For Cell-Based Assays in Drug Discovery Government Support and Funding For Cell-Based Research Growing Efforts To Curtail Animal-Based Studies Rising Prevalence of Cancer Alliances To Accelerate Innovations in Drug Discovery Restraints High Cost of Instruments and Restrictions Imposed by Product End-User Licenses For Reagents Lack of Standardization of Protocols Used in Cell-Based Assays Opportunities Growing Applications of Cell-Based Assays in Chronic Diseases and Personalized Medicine Growth Opportunities in Emerging Economies Rising Adoption of AI in Drug Discovery and Cell Analysis Challenges Complexities in Assay Designs Shortage of Skilled Professionals Company Profiles Danaher Thermo Fisher Scientific Inc. Merck Kgaa BD Agilent Technologies, Inc. Lonza Eurofins Scientific Charles River Laboratories Bio-Rad Laboratories, Inc. Revvity Sartorius Ag Corning Incorporated Promega Corporation Cell Signaling Technology, Inc. Enzo Biochem Inc. Carna Biosciences, Inc. Intertek Group Plc Bico Cell Biolabs, Inc. Reaction Biology AAT Bioquest, Inc. Pestka Biomedical Laboratories, Inc. Neuromics BPS Bioscience, Inc. Bellbrook Labs Profacgen Bmg Labtech Gmbh Hanugen Therapeutics Altogen Labs Bioagilytix Labs For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell Based Assays Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
